[go: up one dir, main page]

DE60022227D1 - 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung - Google Patents

2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung

Info

Publication number
DE60022227D1
DE60022227D1 DE60022227T DE60022227T DE60022227D1 DE 60022227 D1 DE60022227 D1 DE 60022227D1 DE 60022227 T DE60022227 T DE 60022227T DE 60022227 T DE60022227 T DE 60022227T DE 60022227 D1 DE60022227 D1 DE 60022227D1
Authority
DE
Germany
Prior art keywords
indol
oxo
acetamide
antitumoral effect
antitumoral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60022227T
Other languages
English (en)
Other versions
DE60022227T2 (de
Inventor
Ernesto Menta
Nicoletta Pescalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Therapeutics Europe SRL
Original Assignee
Cell Therapeutics Europe SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Europe SRL filed Critical Cell Therapeutics Europe SRL
Publication of DE60022227D1 publication Critical patent/DE60022227D1/de
Application granted granted Critical
Publication of DE60022227T2 publication Critical patent/DE60022227T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60022227T 1999-12-23 2000-12-21 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung Expired - Fee Related DE60022227T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999MI002693A IT1315267B1 (it) 1999-12-23 1999-12-23 Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
ITMI992693 1999-12-23
PCT/EP2000/013068 WO2001047916A1 (en) 1999-12-23 2000-12-21 2-(1h-indol-3-yl)-2-oxo-acetamides with antitumor activity

Publications (2)

Publication Number Publication Date
DE60022227D1 true DE60022227D1 (de) 2005-09-29
DE60022227T2 DE60022227T2 (de) 2006-06-22

Family

ID=11384182

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60022227T Expired - Fee Related DE60022227T2 (de) 1999-12-23 2000-12-21 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung

Country Status (24)

Country Link
US (1) US6753342B2 (de)
EP (1) EP1244652B1 (de)
JP (1) JP2003519140A (de)
KR (1) KR100795533B1 (de)
CN (1) CN1250542C (de)
AT (1) ATE302772T1 (de)
AU (1) AU776332B2 (de)
BR (1) BR0016553A (de)
CA (1) CA2395205A1 (de)
CZ (1) CZ20022170A3 (de)
DE (1) DE60022227T2 (de)
EA (1) EA004925B1 (de)
ES (1) ES2246918T3 (de)
HU (1) HUP0203524A3 (de)
IL (2) IL150329A0 (de)
IT (1) IT1315267B1 (de)
MX (1) MXPA02006217A (de)
NO (1) NO323312B1 (de)
NZ (1) NZ519689A (de)
PL (1) PL356541A1 (de)
SK (1) SK285682B6 (de)
TR (1) TR200201613T2 (de)
WO (1) WO2001047916A1 (de)
ZA (1) ZA200204964B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE330955T1 (de) 1998-04-28 2006-07-15 Elbion Ag Indolderivate und deren verwendung als inhibitoren der phosphodiesterase 4.
IT1318641B1 (it) * 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
CN101602756B (zh) * 2002-07-09 2014-11-12 法斯根公司 化合物、含该化合物的药物组合物以及该化合物的应用方法
BRPI0414313A (pt) 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
WO2005094816A1 (en) * 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd Indol-1-yl-acetic acid derivatives
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
SI2007756T1 (sl) 2006-04-07 2015-11-30 Vertex Pharmaceuticals Incorporated Modulatorji prenašalcev z atp-vezavno kaseto
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2049520A4 (de) * 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc Indolverbindungen
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX2012012204A (es) 2010-04-22 2012-12-05 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
HK1209318A1 (en) 2012-07-16 2016-04-01 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
DK3925607T3 (da) 2014-04-15 2023-08-21 Vertex Pharma Farmaceutiske sammensætninger til behandlingen af cystisk fibrosetransmembrankonduktansregulator-medierede sygdomme
CN115785079B (zh) * 2022-11-28 2024-02-13 沈阳药科大学 4-(1h-吲哚-5-基)氨基呋喃-2(5h)-酮类化合物及其制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225465A1 (en) * 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
CO4970714A1 (es) 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
ATE330955T1 (de) * 1998-04-28 2006-07-15 Elbion Ag Indolderivate und deren verwendung als inhibitoren der phosphodiesterase 4.

Also Published As

Publication number Publication date
BR0016553A (pt) 2002-09-17
TR200201613T2 (tr) 2002-10-21
AU2170401A (en) 2001-07-09
AU776332B2 (en) 2004-09-02
NO323312B1 (no) 2007-03-12
ZA200204964B (en) 2004-01-29
CA2395205A1 (en) 2001-07-05
WO2001047916A1 (en) 2001-07-05
HUP0203524A3 (en) 2008-01-28
NZ519689A (en) 2004-02-27
EP1244652B1 (de) 2005-08-24
PL356541A1 (en) 2004-06-28
US20030158153A1 (en) 2003-08-21
CN1413205A (zh) 2003-04-23
DE60022227T2 (de) 2006-06-22
ES2246918T3 (es) 2006-03-01
IT1315267B1 (it) 2003-02-03
KR20020063247A (ko) 2002-08-01
HUP0203524A2 (hu) 2003-03-28
ATE302772T1 (de) 2005-09-15
KR100795533B1 (ko) 2008-01-16
NO20022976D0 (no) 2002-06-20
IL150329A (en) 2006-07-05
IL150329A0 (en) 2002-12-01
EA200200558A1 (ru) 2002-12-26
NO20022976L (no) 2002-06-20
JP2003519140A (ja) 2003-06-17
EP1244652A1 (de) 2002-10-02
MXPA02006217A (es) 2004-02-26
CN1250542C (zh) 2006-04-12
CZ20022170A3 (cs) 2002-09-11
US6753342B2 (en) 2004-06-22
SK285682B6 (sk) 2007-06-07
ITMI992693A0 (it) 1999-12-23
ITMI992693A1 (it) 2001-06-23
SK8962002A3 (en) 2002-11-06
EA004925B1 (ru) 2004-10-28

Similar Documents

Publication Publication Date Title
DE60022227D1 (de) 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung
DE69918422D1 (de) Phthalazinone pde iii/iv hemmer
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
ATE258930T1 (de) Dihydrobenzifurane
MY128709A (en) Phosphonites
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
PT1202954E (pt) Novas aminobenzofenonas
SE9903290D0 (sv) Novel compounds
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
MXPA04000506A (es) Nuevos derivados de et-743 antitumorales.
DE60202669D1 (de) 6-phenylbenzonaphthyidine
MA24197A1 (fr) Nouvelles fungarrestines
ES2159489A1 (es) Nuevos derivados de imidazol con actividad antiinflamatoria.
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
DE59901563D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
ATE243698T1 (de) 1,2-dihydro-1-oxo-pyrazino(1,2-)indolederivate
ES2166710A1 (es) Nuevos compuestos heterociclicos con actividad antiinflamatoria.
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων
DE602004018276D1 (de) Nitratester von phenylaminothiophen-essigsäurederivaten
CY1110467T1 (el) 2-(ετερο-)αρυλιο υποκατεστημενα παραγωγα τετραϋδροκινολινης

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee